The DOI matches its Crossref record.
Sildenafil, a novel effective oral therapy for male erectile dysfunction
Abstract
Objectives: To determine the efficacy and safety of sildenafil, a novel orally active inhibitor of the type‐V cyclic guanosine monophosphate‐specific phosphodiesterase (the predominant isoenzyme in the human corpus cavernosum) on penile erectile activity in patients with male erectile dysfunction of no established organic cause. Patients and methods: Twelve patients (aged 36–63 years) with male erectile dysfunction of no established organic cause were entered into a double‐blind, randomized, placebo‐controlled, crossover study which was conducted in two phases. In the first phase (four‐way crossover), treatment efficacy was evaluated by measurements of penile rigidity using penile plethysmography during visual sexual stimulation at different doses of sildenafil (10, 25 and 50 mg or placebo). In the second phase (two‐way crossover), efficacy was assessed by a diary record of penile erectile activity after single daily doses of sildenafil (25 mg) or placebo for 7 days. Results: The mean (95% confidence interval, CI) duration of rigidity of >80% at the base of the penis was 1.3 min (0.4–3.1) in patients on placebo, 3.5 min (1.6–7.3; P = 0.009) on 10 mg, 8.0 min (3.7–16.7; P = 0.003) on 25 mg and 11.2 min (5.6–22.3; P < 0.001) on 50 mg of sildenafil. The mean (95% CI) duration of rigidity of >80% at the tip of the penis was 1.2 min (0.4–2.7) on placebo and 7.4 min (2.4–8.5; P =0.001) on 50 mg sildenafil. From the diary record of daily erectile activity, the mean (95% CI) total number of erections was significantly higher in patients receiving sildenafil was 6.1 (3.2–11.4), compared with 1.3 (0.5–2.7) in those on placebo; 10 of 12 patients reported improved erectile activity while receiving sildenafil, compared with two of 12 on placebo ( P = 0.018). Six patients on active treatment and five on placebo reported mild and transient adverse events which included headache, dyspepsia and pelvic musculo‐skeletal pain. Conclusion: These results show that sildenafil is a well tolerated and effective oral therapy for male erectile dysfunction with no established organic cause and may represent a new class of peripherally acting drug for the treatment of this condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Sexual Dysfunction in the United States: Prevalence and Predictors
Laumann, E. O., Paik, A., & Rosen, R. C. (1999) · JAMA · doi:10.1001/jama.281.6.537 · Cited by 5,119
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
The International Index of Erectile Function (IIEF): a state-of-the-science review
Rosen, R. C., Cappelleri, J. C., & Gendrano, N. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900857 · Cited by 1,044
Oral Sildenafil in the Treatment of Erectile Dysfunction
(1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390121 · Cited by 622
Metadata
- Authors
- Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J.
- Venue
- British Journal of Urology
- Publisher
- Wiley
- Published
- 1996-08
- Volume
- 78
- Issue
- 2
- Pages
- 257-261
- ISSN
- 0007-1331 (ISSN-L)
- OpenAlex
- W2115742279
- Cited by
- 564
- References
- 0
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sildenafil, a novel effective oral therapy for male erectile dysfunction. https://app.cochat.ai/papers/10.1046/j.1464-410x.1996.10220.x
- The paper
- Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J. (1996). Sildenafil, a novel effective oral therapy for male erectile dysfunction. British Journal of Urology. https://doi.org/10.1046/j.1464-410x.1996.10220.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.